March 28, 2025
None
Office of The Director, National Institutes of Health (OD)
Institutional Biosafety Committees (IBCs) serve as a critical linchpin in ensuring the safe and responsible conduct of research. Since the issuance of the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) in 1976, IBCs have expanded in number to the thousands and have voluntarily expanded their roles to encompass new research approaches as they arise.
IBCs continue to serve as a pillar of biosafety oversight and are essential in building trust on behalf of the biomedical research enterprise. Under the NIH Guidelines, this expectation is a mandate and as such, NIH is reinforcing its commitment to working with IBCs to ensure transparency in biosafety oversight by updating its implementation expectations to protect the safety of all Americans.
To maximally meet the transparency aims of the NIH Guidelines, on June 1, 2025:
Please direct all inquiries to:
NIH Office of Science Policy